Targeting Prodromal Alzheimer Disease With Avagacestat-Reference-Cited by-同舟云学术

Targeting Prodromal Alzheimer Disease With Avagacestat

Published:2015-11-01 Issue:11 Volume:72 Page:1324
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Coric Vladimir¹,Salloway Stephen²,van Dyck Christopher H.³,Dubois Bruno⁴,Andreasen Niels⁵,Brody Mark⁶,Curtis Craig⁷,Soininen Hilkka⁸,Thein Stephen⁹,Shiovitz Thomas¹⁰,Pilcher Gary¹,Ferris Steven¹¹,Colby Susan¹,Kerselaers Wendy¹,Dockens Randy¹,Soares Holly¹,Kaplita Stephen¹,Luo Feng¹,Pachai Chahin¹²,Bracoud Luc¹²,Mintun Mark¹³,Grill Joshua D.¹⁴,Marek Ken¹⁵,Seibyl John¹⁵,Cedarbaum Jesse M.¹,Albright Charles¹,Feldman Howard H.¹⁶,Berman Robert M.¹

Affiliation:

1. Global Clinical Research, Bristol-Myers Squibb, Wallingford, Connecticut

2. Department of Neurology, Brown Medical School, Butler Hospital, Providence, Rhode Island

3. Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut

4. Dementia Research Center, Department of Neurology, Cognition, Neuro-imagerie et maladies du Cerveau, University Pierre et Marie Curie Paris 6, Hôpital de la Salpétrière, Paris, France

5. Department of Neurobiology, Karolinska Institute, Stockholm, Sweden

6. Brain Matters Research, Delray Beach, Florida

7. Compass Research, Orlando, Florida

8. Department of Neurology, University of Eastern Finland, Kuopio, Finland

9. Pacific Research Network Inc, San Diego, California

10. California Neuroscience Research Medical Group Inc, Sherman Oaks

11. Department of Psychiatry, New York University Langone Medical Center, New York

12. BioClinica Inc, Newtown, Pennsylvania

13. Avid Radiopharmaceuticals, Philadelphia, Pennsylvania

14. Mary S. Easton Center for Alzheimer’s Disease Research, University of California at Los Angeles

15. Institute for Neurodegenerative Disorders, New Haven, Connecticut

16. University of British Columbia, Vancouver, British Columbia, Canada